In the last trading session, 1,387,747 shares of the Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were traded, and its beta was 0.31. Most recently the company’s share price was $10.47, and it changed around -$0.64 or -0.06% from the last close, which brings the market valuation of the company to $781.42 Million. KPTI currently trades at a discount to its 52-week high of $25.98, offering almost -148.14% off that amount. The share price’s 52-week low was $9.75, which indicates that the current value has risen by an impressive 6.88% since then. We note from Karyopharm Therapeutics Inc.’s average daily trading volume that its 10-day average is 2.02 Million shares, with the 3-month average coming to 2.68 Million.
Karyopharm Therapeutics Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.7. If we narrow it down even further, the data shows that none out of 10 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended KPTI as a Hold, whereas 8 deemed it a Buy, and no one rated it as Underweight. Karyopharm Therapeutics Inc. is expected to report earnings per share of -$0.68 for the current quarter.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Trading Information
Although KPTI has showed a red trend with a performance of -5.76% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $11.17 on Tuesday, Apr 06 increased the stock’s daily price by 6.27%. The company’s shares are currently down -0.32% year-to-date, but still up 0.0629 over the last five days. On the other hand, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is -0.1% down in the 30-day period. We can see from the shorts that 15.59 Million shares have been sold at a short interest cover period of 5.82 day (s).
The consensus price target as assigned by Wall Street analysts is $30, which translates to bears needing to increase their stock price by 186.53% from its current value. Analyst projections state that KPTI is forecast to be at a low of $21 and a high of $49. In order for the stock price to hit the forecast high, the stock would need to surge +368% from its current level, while the stock would need to crash 100.57% from its current level to reach the projected low.
Karyopharm Therapeutics Inc. (KPTI) projections and forecasts
Karyopharm Therapeutics Inc. share prices are not performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -26.42 percent over the past six months and at a -22.06% annual growth rate that is well below the industry average of 17.3%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain +12.8% in revenue this quarter, and will report an increase of 1.6% in the next quarter. The year-over-year growth rate is expected to be 44.5%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of $26.27 Million in revenue for the current quarter. 9 analysts expect Karyopharm Therapeutics Inc. to make $32.89 Million in revenue for the quarter ending June 01, 2021. The company’s sales for the same quarters a year ago were $18.14 Million and $33.51 Million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 44.8%. Forecasts for the next quarter put sales growth at -1.9%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 3.9%. Karyopharm Therapeutics Inc. earnings are expected to increase by 15.4% in 2021, but the outlook is negative 0% per year for the next five years.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 9.54% of Karyopharm Therapeutics Inc. shares, and 87.86% of them are in the hands of institutional investors. The stock currently has a share float of 97.12%. Karyopharm Therapeutics Inc. stock is held by 241 institutions, with Blackrock Inc. being the largest institutional investor. By Dec 30, 2020, it held 10.02% of the shares, which is about 7.48 Million shares worth $115.71 Million.
State Street Corporation, with 7.15% or 5.34 Million shares worth $82.66 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Feb 27, 2021. The former held 4173986 shares worth $57.68 Million, making up 5.59% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 1.79 Million shares worth around $27.66 Million, which represents about 2.39% of the total shares outstanding.